A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Name: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Creator: Vivli
Published: 2025-04-01 01:04:28
License: 暂无描述

DataCite Commons2025-04-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00007864/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.

提供机构：

Vivli

创建时间：

2022-05-25